Sökning: "PD-1"

Visar resultat 1 - 5 av 28 avhandlingar innehållade ordet PD-1.

  1. 1. The PD-1 pathway and the complement system in systemic lupus erythematosus

    Detta är en avhandling från Uppsala : Acta Universitatis Upsaliensis

    Författare :Helga Kristjánsdóttir; Uppsala universitet.; [2009]
    Nyckelord :NATURVETENSKAP; NATURAL SCIENCES; SLE; autoimmune diseases; PD-1; C4AQ0; low MBL; multicase family; NATURAL SCIENCES Biology Cell and molecular biology Immunology; NATURVETENSKAP Biologi Cell- och molekylärbiologi Immunologi; medicinsk genetik; Medical Genetics;

    Sammanfattning : Autoimmune diseases occur in up to 3-5% of the general population and represent a diverse collection of diseases with regards to clinical manifestations. The unifying factor of autoimmune diseases is tissue and organ damage as a result of an immune response mounted against self-antigens. LÄS MER

  2. 2. Immunological Checkpoint Blockade and TLR Stimulation for Improved Cancer Therapy

    Detta är en avhandling från Uppsala : Acta Universitatis Upsaliensis

    Författare :Sara Mangsbo; Uppsala universitet.; [2009]
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; CpG ODNs; TLR-9; CTLA-4; PD-1; PD-L1; B7. H1; immunotherapy; checkpoint blockade; bladder cancer; cancer; complement; TLRs; Compstatin; properdin; C3; experimental animal model; whole blood loop system; combination therapies; MEDICINE Microbiology; immunology; infectious diseases Immunology Clinical immunology; MEDICIN Mikrobiologi; immunologi; infektionssjukdomar Immunologi Klinisk immunologi; MEDICINE Microbiology; immunology; infectious diseases Immunology Tumour immunology; MEDICIN Mikrobiologi; immunologi; infektionssjukdomar Immunologi Tumörimmunologi; immunologi; Immunology;

    Sammanfattning : This thesis concerns the investigation of novel immunotherapies for cancer eradication. CpG therapy was used in order to target antigen-presenting cells (APCs), facilitating antigen presentation and activation of T cells. LÄS MER

  3. 3. Epidemiology and prognosis in classical Hodgkin lymphoma

    Detta är en avhandling från Uppsala : Acta Universitatis Upsaliensis

    Författare :Peter Hollander; Uppsala universitet.; [2018]
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Epstein-Barr virus; rheumatoid arthritis; tumor microenvironment; immunohistochemistry; immune checkpoints; regulatory T lymphocytes; PD-1; PD-L1; Oncology; Onkologi; Patologi; Pathology;

    Sammanfattning : Classical Hodgkin lymphoma (HL) is a B cell derived neoplasm with an overall good prognosis. Its etiology and pathogenesis are largely unknown. The tumor microenvironment consists of sparse malignant cells and abundant leukocytes. LÄS MER

  4. 4. Antibody-based immunotherapy of cancer From optimization to novel approaches

    Detta är en avhandling från Uppsala : Acta Universitatis Upsaliensis

    Författare :Luuk van Hooren; Uppsala universitet.; [2018]
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Cancer immunotherapy; CD40; CTLA-4; PD-1; Gal-1; tertiary lymphoid structures;

    Sammanfattning : Antibody immunotherapy is a successful therapeutic approach to treat cancer. The overall aim of this thesis is to investigate the mechanisms of antibody-based immunotherapies and the role of the tumor microenvironment in mediating the anti-tumor immune response, in order to aid the development of improved immunotherapies for cancer patients. LÄS MER

  5. 5. Smoking and T cell co-stimulation in rheumatoid arthritis

    Detta är en avhandling från Göteborg : BrandFactory AB

    Författare :Caroline Wasén; Göteborgs universitet.; Gothenburg University.; [2019]
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; rheumatoid arthritis; CD8 T cell; programmed cell death-1; programmed cell death-1 ligand 1; smoking; microRNA;

    Sammanfattning : In this thesis I investigated if smoking limits the co-stimulatory system of CD8+ T cells in rheumatoid arthritis (RA). I took special interest in the co-inhibitory receptor PD-1 and its ligand PD-L1. LÄS MER